Get regular updates to your inbox.
Tilray Canada has launched its newest product, Tilray 2:100, a formulation of therapeutic cannabis oil containing a high concentration of cannabidiol (CBD), which may help treat Canadian patients with conditions like Dravet syndrome. “We are excited to offer this highly concentrated CBD product to patients in Canada. We…
Biscayne Neurotherapeutics has licensed the Chinese rights to its investigative antiepileptic therapy BIS-001ER to Global Drug Development Centre (GDCC) China in Taiwan, China, Hong Kong, and Macau. Biscayne is developing BIS-001ER to treat refractory forms of focal epilepsy, including catastrophic pediatric-onset epilepsies such as Dravet syndrome and Lennox Gastaut. “BIS-001ER is…
GW Pharmaceuticals announced that it recently received allowance notices from the U.S. Patent and Trademark Office (USPTO) for five new patent applications for Epidiolex (cannabidiol). Three of these applications specifically focus on methods to reduce the frequency of seizures in patients with a form of Dravet syndrome. Notices of allowance…
Get regular updates to your inbox.